Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 1/20 | 0.51 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.51 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.51 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.47 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.46 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.44 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.44 |
| ▸ | OXTR | P30559 | 1/20 | 0.44 |
| ▸ | CALCR | P30988 | 4/20 | 0.43 |
| ▸ | REN | P00797 | 1/20 | 0.43 |
| ▸ | SRC | P12931 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30660774 | 1.00 | MAPK8 (0.51) | MAPK8MAPK9MAPK10CALCRLKEAP1 | |
| SCHEMBL30660804 | 1.00 | MAPK8 (0.51) | MAPK8MAPK9MAPK10CALCRLKEAP1 | |
| SCHEMBL30660778 | 1.00 | MAPK8 (0.51) | MAPK8MAPK9MAPK10CALCRLKEAP1 | |
| SCHEMBL30660806 | 1.00 | MAPK8 (0.51) | MAPK8MAPK9MAPK10CALCRLKEAP1 | |
| SCHEMBL30660775 | 1.00 | MAPK8 (0.51) | MAPK8MAPK9MAPK10CALCRLKEAP1 | |
| SCHEMBL30660787 | 1.00 | MAPK8 (0.51) | MAPK8MAPK9MAPK10CALCRLKEAP1 | |
| SCHEMBL30660803 | 1.00 | MAPK8 (0.51) | MAPK8MAPK9MAPK10CALCRLKEAP1 | |
| SCHEMBL30660788 | 1.00 | MAPK8 (0.51) | MAPK8MAPK9MAPK10CALCRLKEAP1 | |
| SCHEMBL30660783 | 1.00 | MAPK8 (0.51) | MAPK8MAPK9MAPK10CALCRLKEAP1 | |
| SCHEMBL30660785 | 0.99 | MAPK8 (0.51) | MAPK8MAPK9MAPK10CALCRLKEAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240325487-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | ARDELYX, INC. | 2024-10-03 | — | — | US | disclosed |
| US-11813304-B2 | Compounds and methods for inhibiting phosphate transport | ARDELYX, INC. (US) | 2023-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240325487-A1 | COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT | SLC34A3, SLC34A2, SLC34A1 | MAPK8 1993/4885MAPK9 1293/4885MAPK10 1883/4885 |
| US-11813304-B2 | Compounds and methods for inhibiting phosphate transport | SLC34A3, SLC34A2, SLC34A1 | MAPK8 1993/4885MAPK9 1293/4885MAPK10 1883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.